Cibc World Market Inc. Invests $3.60 Million in Edwards Lifesciences Corporation $EW

Cibc World Market Inc. purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, HoldingsChannel.com reports. The institutional investor purchased 39,743 shares of the medical research company’s stock, valued at approximately $3,595,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Edwards Lifesciences in the second quarter worth $5,318,092,000. State Street Corp grew its holdings in shares of Edwards Lifesciences by 1.5% during the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after purchasing an additional 371,892 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Edwards Lifesciences by 4.8% in the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after buying an additional 989,533 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at $1,274,082,000. Finally, Norges Bank bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $803,686,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 0.1%

EW stock opened at $90.93 on Thursday. The company has a market cap of $52.36 billion, a P/E ratio of 52.26, a PEG ratio of 2.38 and a beta of 0.85. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average of $89.43 and a 200-day moving average of $84.91.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 2,425 shares of company stock worth $219,199. Corporate insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on EW shares. Truist Financial upped their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. UBS Group began coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price objective for the company. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Piper Sandler reiterated an “overweight” rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Finally, JPMorgan Chase & Co. increased their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.